Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Premier Research Clear all
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

NCT00626886
View directory record Official record
Conditions
Postoperative Pain, Inguinal Hernia
Interventions
Bupivacaine Collagen Sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
GFT505 80mg, GFT505 120mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Fresno, California • La Jolla, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

NCT02446821
View directory record Official record
Conditions
Contraception
Interventions
VeraCept
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
12
States / cities
Burbank, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

NCT01166412
View directory record Official record
Conditions
Contraception
Interventions
levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional Results available

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

NCT04044664
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Placebo oral capsule, NYX-783
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 4, 2026, 2:18 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

NCT03296098
View directory record Official record
Conditions
Contraception, Healthy Female
Interventions
Ulipristal acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

NCT03124160
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
Mona Lisa® NT Cu380 Mini, ParaGard® TCu380A
Drug
Lead sponsor
FHI 360
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 4, 2026, 2:18 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 66 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Chino, California • Garden Grove, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

NCT02994602
View directory record Official record
Conditions
Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

NCT07453069
View directory record Official record
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT02045901
View directory record Official record
Conditions
Morning Sickness
Interventions
Diclegis, Placebo (Sugar Pill)
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Norwalk, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 4, 2026, 2:18 PM EDT
Not listed Phase 3 Interventional

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

NCT03023540
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Type IA
Interventions
PXT3003
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
17 Years to 67 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

NCT01586000
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
8
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 4, 2026, 2:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
INT230-6, Eribulin, Trabectedin, Pazopanib
Drug
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring

NCT00455156
View directory record Official record
Conditions
Contraception
Interventions
150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

NCT00891228
View directory record Official record
Conditions
Contraception
Interventions
Testosterone, Nestorone®
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

NCT00274261
View directory record Official record
Conditions
Pregnancy
Interventions
C31G, nonoxynol-9 (N-9)
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy

NCT01224145
View directory record Official record
Conditions
Hernia, Postoperative Pain
Interventions
5x5cm bupivacaine collagen sponges
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

NCT02296892
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remimazolam, Placebo, Midazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Brandon, Florida • Sun City Center, Florida • Michigan City, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956
View directory record Official record
Conditions
Childhood-Onset Fluency Disorder (Stuttering)
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 4, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

NCT03785756
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet, Placebo of PR tablet, Placebo of IR tablet
Drug
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 4, 2026, 2:18 PM EDT